v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total revenue $ 87,115 $ 62,422
Cost of services 28,639 25,011
Gross profit 58,476 37,411
Research and development 12,577 11,567
Selling and marketing 18,316 16,085
General and administrative 32,134 23,419
Loss from operations (4,551) (13,660)
Non-operating income (expenses), net    
Change in fair value of warrants (1,100) (6,101)
Interest expense, net (640) (597)
Other income, net 209 37
Total non-operating expenses, net (1,531) (6,661)
Loss before income taxes (6,082) (20,321)
Income tax (expense) benefit (447) 82
Net loss (6,529) (20,239)
Other comprehensive income (loss), net of tax    
Unrealized gain (loss) related to available for sale securities, net 75 (134)
Comprehensive loss $ (6,454) $ (20,373)
Weighted average shares outstanding of Class A common stock, Basic (in shares) 28,147,948 26,062,170
Weighted average shares outstanding of Class A common stock, Diluted (in shares) 28,147,948 26,062,170
Basic loss per share, Class A common stock (in dollars per share) $ (0.23) $ (0.78)
Diluted loss per share, Class A common stock (in dollars per share) $ (0.23) $ (0.78)
Class A common stock    
Other comprehensive income (loss), net of tax    
Weighted average shares outstanding of Class A common stock, Basic (in shares) 28,147,948 26,062,170
Weighted average shares outstanding of Class A common stock, Diluted (in shares) 28,147,948 26,062,170
Basic loss per share, Class A common stock (in dollars per share) $ (0.23) $ (0.78)
Diluted loss per share, Class A common stock (in dollars per share) $ (0.23) $ (0.78)
Diagnostic test revenue    
Total revenue $ 85,759 $ 61,104
Other revenue    
Total revenue $ 1,356 $ 1,318